Equity Overview
Price & Market Data
Price: $2.90
Daily Change: -$0.06 / 2.07%
Range: $2.88 - $3.07
Market Cap: $230,976,400
Volume: 1,486,416
Performance Metrics
1 Week: 13.08%
1 Month: 16.21%
3 Months: 16.21%
6 Months: 177.4%
1 Year: 149.2%
YTD: 56.38%
Company Details
Employees: 213
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Israel
Details
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company offers Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. It operates in the United States, Australia, Canada, Israel, Brazil, Russia, and Turkey. The company is headquartered in Hackensack. New Jersey.